NICE has been busy with announcements today, rejecting Astellas’ Xospata for a certain type of acute myeloid leukaemia (AML) and querying evidence for MSD's Keytruda in head and neck cancer
England’s NHS could prevent hundreds of strokes of unknown cause with a new implantable monitor that transmits data to doctors remotely, which is recommended for funding following draft gui
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
